Top

Current Rheumatology Reports

Published in:

01-12-2018 | Psoriatic Arthritis (J Scher, Section Editor)

Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics

Authors: Rebecca Haberman, Lourdes M. Perez-Chada, Joseph F. Merola, Jose Scher, Alexis Ogdie, Soumya M. Reddy

Published in: Current Rheumatology Reports | Issue 12/2018

Abstract

Purpose of Review

Despite a robust therapeutic landscape, significant gaps exist in the quality of care of psoriatic disease. Thus, an improved understanding of the challenges in providing quality care and the implementation of effective strategies to overcome them is needed. In this review, we summarize the burden of psoriatic disease, discuss the challenges in the care of psoriatic patients, and outline how combined dermatology-rheumatology clinics bridge many of these gaps.

Recent Findings

Multiple challenges are faced in providing high-quality care to patients with psoriasis and psoriatic arthritis from the pre-diagnosis phase of disease to the follow-up period. Challenges are mainly driven by lack of education of patients and healthcare providers, inefficient communication between specialists, lack of a holistic approach to patients, and limitations of available therapies. The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is working on demonstrating the effectiveness of combined dermatology-rheumatology clinics in addressing some of these challenges. Recent findings show that combined clinic models may improve quality of care by raising awareness of psoriatic disease, fostering educational activities for both patients and physicians, and allowing for comprehensive evaluation and management of patients through improved communications between disciplines.

Summary

Psoriasis and psoriatic arthritis are complex diseases that often require an interdisciplinary approach. Thus, combined dermatology-rheumatology clinics and local-regional partnerships are potentially effective in improving quality of care in psoriatic disease.

Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–6. https://doi.org/10.1016/j.jaad.2013.11.013.CrossRefPubMed

Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218–24. https://doi.org/10.1016/j.jaad.2008.09.022.CrossRefPubMed

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification, management of P et al. global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339.CrossRefPubMed

Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–7. https://doi.org/10.1111/j.1365-2133.2008.09023.x.CrossRefPubMed

• Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545–68. https://doi.org/10.1016/j.rdc.2015.07.001 Overview on the epidemiology of psoriatic arthritis. CrossRef

Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548–54. https://doi.org/10.1111/j.1468-3083.2009.03463.x.CrossRefPubMed

Gottlieb AB, Mease PJ, Mark Jackson J, Eisen D, Amy Xia H, Asare C, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’ offices. J Dermatol Treat. 2006;17(5):279–87. https://doi.org/10.1080/09546630600823369.CrossRef

Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011;7(10):588–98. https://doi.org/10.1038/nrrheum.2011.125.CrossRefPubMed

Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460–8. https://doi.org/10.1093/rheumatology/keg384.CrossRef

10.

Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17(6):809–12.PubMed

11.

Tezel N, Yilmaz Tasdelen O, Bodur H, Gul U, Kulcu Cakmak S, Oguz ID, et al. Is the health-related quality of life and functional status of patients with psoriatic arthritis worse than that of patients with psoriasis alone? Int J Rheum Dis. 2015;18(1):63–9. https://doi.org/10.1111/1756-185X.12283.CrossRefPubMed

12.

•• Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8. https://doi.org/10.1016/j.jaad.2016.10.017 Study describing the current treatment trends in psoriasis and demonstrating the level of undertreatment in psoriatic disease.CrossRefPubMed

13.

Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden—a cross-sectional study. Eur J Dermatol. 2012;22(2):238–45. https://doi.org/10.1684/ejd.2011.1635.CrossRefPubMed

14.

Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J Rheumatol. 2016;43(1):88–96. https://doi.org/10.3899/jrheum.150540.CrossRefPubMed

15.

Tillett W, Shaddick G, Askari A, Cooper A, Creamer P, Clunie G, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015;54(1):157–62. https://doi.org/10.1093/rheumatology/keu264.CrossRef

16.

Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14(5):377–88. https://doi.org/10.1007/s40257-013-0032-x.CrossRefPubMed

17.

Helliwell P, Coates L, Chandran V, Gladman D, de Wit M, FitzGerald O, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014;66(12):1759–66. https://doi.org/10.1002/acr.22404.CrossRefPubMedPubMedCentral

18.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/north American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–35. https://doi.org/10.1016/j.jaad.2013.07.023.CrossRefPubMed

19.

Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–40. https://doi.org/10.1136/annrheumdis-2012-201706.CrossRefPubMed

20.

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–8. https://doi.org/10.1016/j.jaad.2015.05.001.CrossRefPubMed

21.

Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–5. https://doi.org/10.1001/jamadermatol.2013.5264.CrossRefPubMed

22.

• Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the Management of Psoriasis and Psoriatic Arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. https://doi.org/10.1007/s40257-015-0169-x Large study looking at the barriers to systemic medication use in psoriatic disease. CrossRefPubMed

23.

Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118–26. https://doi.org/10.1097/bor.0000000000000152.CrossRefPubMed

24.

Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485–96.CrossRef

25.

Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–4.PubMed

26.

Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–92.CrossRef

27.

Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7.CrossRef

28.

Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–92. https://doi.org/10.1111/j.1365-2133.2010.09941.x.CrossRefPubMedPubMedCentral

29.

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. https://doi.org/10.1001/jama.296.14.1735.CrossRefPubMed

30.

Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–32. https://doi.org/10.1136/annrheumdis-2014-205675.CrossRefPubMed

31.

Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6. https://doi.org/10.1136/annrheumdis-2011-201194.CrossRefPubMed

32.

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29. https://doi.org/10.1111/jdv.12163.CrossRefPubMed

33.

Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666. https://doi.org/10.1136/bmj.b5666.CrossRefPubMed

34.

Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017;69(1):51–7. https://doi.org/10.1002/acr.23094.CrossRef

35.

Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res. 2014;66(4):600–7. https://doi.org/10.1002/acr.22185.CrossRef

36.

Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford). 2008;47(5):718–23. https://doi.org/10.1093/rheumatology/ken090.CrossRef

37.

Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331–4. https://doi.org/10.1089/met.2009.0124.CrossRefPubMedPubMedCentral

38.

Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res. 2011;63(2):195–202. https://doi.org/10.1002/acr.20363.CrossRef

39.

Ozkan SG, Yazisiz H, Behlul A, Gokbelen YA, Borlu F, Yazisiz V. Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis. Eur J Rheumatol. 2017;4(1):40–5. https://doi.org/10.5152/eurjrheum.2017.16052.CrossRefPubMedPubMedCentral

40.

di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res. 2013;65(1):141–7. https://doi.org/10.1002/acr.21711.CrossRef

41.

Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813–7. https://doi.org/10.1136/annrheumdis-2013-204448.CrossRefPubMed

42.

Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Investig Dermatol. 2012;132(3 Pt 1):556–62. https://doi.org/10.1038/jid.2011.365.CrossRefPubMed

43.

Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5. https://doi.org/10.1111/j.1468-3083.2008.03031.x.CrossRefPubMed

44.

Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013;72(7):1200–5. https://doi.org/10.1136/annrheumdis-2012-202143.CrossRefPubMed

45.

Breban M. Gut microbiota and inflammatory joint diseases. Joint Bone Spine. 2016;83(6):645–9. https://doi.org/10.1016/j.jbspin.2016.04.005.CrossRefPubMed

46.

Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij V, van der Woude CJ, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783–9. https://doi.org/10.1097/mib.0000000000001169.CrossRefPubMed

47.

Rehal B, Modjtahedi BS, Morse LS, Schwab IR, Maibach HI. Ocular psoriasis. J Am Acad Dermatol. 2011;65(6):1202–12. https://doi.org/10.1016/j.jaad.2010.10.032.CrossRefPubMed

48.

Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35(4):354–6.CrossRef

49.

Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999–1002. https://doi.org/10.1007/s10067-015-2960-8.CrossRefPubMed

50.

Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Association of psoriatic disease with uveitis: a Danish Nationwide cohort study. JAMA Dermatol. 2015;151(11):1200–5. https://doi.org/10.1001/jamadermatol.2015.1986.CrossRefPubMed

51.

Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–5. https://doi.org/10.1001/archdermatol.2010.186.CrossRefPubMedPubMedCentral

52.

Dommasch ED, Li T, Okereke OI, Li Y, Qureshi AA, Cho E. Risk of depression in women with psoriasis: a cohort study. Br J Dermatol. 2015;173(4):975–80. https://doi.org/10.1111/bjd.14032.CrossRefPubMedPubMedCentral

53.

McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887–96. https://doi.org/10.3899/jrheum.130797.CrossRefPubMed

54.

Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76(11):1906–10. https://doi.org/10.1136/annrheumdis-2017-211284.CrossRefPubMed

55.

Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957–62. https://doi.org/10.1016/j.jaad.2007.06.042.CrossRefPubMed

56.

Favier G, Gladman DD, Merola JF, Armstrong AW, Boehncke WH, Helliwell PS. Benchmarking care in psoriatic arthritis—the QUANTUM report: a report from the GRAPPA 2016 annual meeting. J Rheumatol. 2017;44(5):674–8. https://doi.org/10.3899/jrheum.170142.CrossRefPubMed

57.

Cohen JM, Husni ME, Qureshi AA, Merola JF. Psoriatic arthritis: it’s as easy as “PSA”. J Am Acad Dermatol. 2015;72(5):905–6. https://doi.org/10.1016/j.jaad.2014.12.008.CrossRefPubMed

58.

Polachek A, Li S, Chandran V, Gladman DD. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken). 2017;69(11):1685–91. https://doi.org/10.1002/acr.23174.CrossRefPubMed

59.

Spadaro A, Iagnocco A, Perrotta FM, Modesti M, Scarno A, Valesini G. Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis. Rheumatology (Oxford). 2011;50(11):2080–6. https://doi.org/10.1093/rheumatology/ker284.CrossRef

60.

Sunkureddi P, Doogan S, Heid J, Benosman S, Ogdie A, Martin L, et al. Evaluation of self-reported patient experiences: insights from digital patient communities in psoriatic arthritis. J Rheumatol. 2018;45(5):638–47. https://doi.org/10.3899/jrheum.170500.CrossRefPubMed

61.

Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49(5):897–9. https://doi.org/10.1067/S0190.CrossRefPubMed

62.

Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals—a report on an implementation meeting. J Eur Acad Dermatol Venereol. 2011;25(Suppl 3):1–13. https://doi.org/10.1111/j.1468-3083.2011.04033.x.CrossRefPubMed

63.

Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152–4. https://doi.org/10.1136/ard.2011.150938.CrossRefPubMed

64.

Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045–50. https://doi.org/10.1136/annrheumdis-2013-204858.CrossRefPubMed

65.

•• Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489–98. https://doi.org/10.1016/s0140-6736(15)00347-5 Important study on showing improved psoriatic arthritis outcomes in patients who are treated early and aggressively. CrossRefPubMedPubMedCentral

66.

Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33. https://doi.org/10.1016/j.jaad.2008.03.045.CrossRefPubMed

67.

Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PC, Kobelt G, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol. 2012;26(Suppl 4):1–16. https://doi.org/10.1111/j.1468-3083.2012.04576.x.CrossRefPubMed

68.

Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233–9. https://doi.org/10.1002/art.24172.CrossRefPubMedPubMedCentral

69.

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(2):262–9. https://doi.org/10.1016/j.jaad.2012.07.007.CrossRefPubMed

70.

Mody E, Husni ME, Schur P, Qureshi AA. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol. 2007;157(5):1050–1. https://doi.org/10.1111/j.1365-2133.2007.08139.x.CrossRefPubMed

71.

•• Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res. 2012;304(1):7–13. https://doi.org/10.1007/s00403-011-1172-6 Seminal study showing the effects of a combined rheumatology-dermatology clinic.CrossRefPubMed

72.

•• Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF. Psoriasis and psoriatic arthritis clinics multicenter advancement network consortium (PPACMAN) survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44(5):693–4. https://doi.org/10.3899/jrheum.170148 Great overview of the benefits and challenges to combined clinics. CrossRefPubMed

73.

PPACMAN. PPACMAN Mission. 2018. http://www.ppacman.org/about.html. Accessed 1 Jul 2018.

74.

Gn C, Conway D, Cunha J, Qureshi AA, Paek SY, Reginato AM. Patient outcomes from a tertiary center combined rheumatology-dermatology-clinic [abstract]. Arthritis Rheum. 2017. 69(suppl). https://acrabstracts.org/abstract/patient-outcomes-from-a-tertiary-center-combined-rheumatology-dermatology-clinic/. Accessed 1 Jul 2018.

Title: Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics
Authors: Rebecca Haberman
Lourdes M. Perez-Chada
Joseph F. Merola
Jose Scher
Alexis Ogdie
Soumya M. Reddy
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Rheumatology Reports / Issue 12/2018
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-018-0785-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2018

Chronic Periaortitis: an Update

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?

Bone Microdamage in Acute Knee Injury

Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis

Use of Physical Activity Monitors in Rheumatic Populations

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage